ABT ▼ -1.2% - Abbott Laboratories $ABT - Abbott receives FDA approval for its TactiFlex™ Duo Ablation Catheter to treat people with abnormal heart rhythms Abbott Laboratories shares fell 1.2% today following FDA approval of its TactiFlex™ Duo Ablation Catheter, a device designed to treat abnormal heart rhythms. The decline suggests investors may have already priced in positive regulatory expectations, or the market is taking profits ahead of the product's commercial launch. 08-SEP-2026 08:02 AM ET